BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
– New follow-up results from Phase 3 SEQUOIA trial and post hoc safety analyses for BRUKINSA® (zanubrutinib) reinforce potential across…